Company Filing History:
Years Active: 2025
Title: Innovations in Cancer Treatment by Nicholas Gimbrone
Introduction
Nicholas Gimbrone is an accomplished inventor based in Atlanta, GA, known for his significant contributions to cancer research. His work primarily focuses on developing innovative treatments for lung cancer, particularly in cases where the STK11 gene is lost. With a strong commitment to improving patient outcomes, Gimbrone has made strides in the field of immunotherapy.
Latest Patents
Nicholas Gimbrone holds a patent for the treatment of STK11-loss cancers. This patent outlines a method for restoring the efficacy of immunotherapy in lung cancer patients with lost STK11 function. The invention involves the use of an ornithine decarboxylase (ODC) inhibitor, such as difluoromethylornithine, to sensitize lung cancer to immunotherapy. The method includes assaying the subject for STK11 function and administering immunotherapy, such as anti-PD-1/PD-L1 immunotherapy.
Career Highlights
Gimbrone is affiliated with the H. Lee Moffitt Cancer Center and Research Institute, Inc., where he collaborates with leading experts in cancer research. His dedication to advancing cancer treatment has positioned him as a key figure in the field.
Collaborations
Throughout his career, Nicholas Gimbrone has worked alongside notable colleagues, including Douglas W. Cress and John Cleveland. These collaborations have fostered a dynamic research environment, contributing to the development of innovative cancer therapies.
Conclusion
Nicholas Gimbrone's work exemplifies the intersection of innovation and medical research, particularly in the treatment of lung cancer. His patent for treating STK11-loss cancers highlights the potential for new therapeutic approaches in oncology.